Biotech takes Trump presidency as a green light — and end to drug price worries

An earlier version of this report had typos in the names of Paul Yook and Andrew McDonald. It has been corrected.

Getty Images

Fears of regulation kept biotech and pharmaceutical investors on the sidelines. Post-election, they’ve been diving back in.

After a rocky election season, drug companies and sector investors are taking President-elect Donald Trump’s victory as a green light.

The renewed bullishness has since found support in the president-elect’s transition website, which omits regulatory moves once proposed by his campaign and instead forecasts less regulation in the space.

Biotech stock fund XBI XBI, -0.62% and pharmaceutical fund XPH XPH, -0.26% both had their second-biggest moves ever the day after the presidential election, second only to a larger move during the 2008 financial crisis.

>>> Original Source <<<